Skip to main content
. 2022 Jun 15;14(12):2950. doi: 10.3390/cancers14122950

Table 1.

Clinical trials evaluating platinum therapy for HRD tumor types.

Type of Tumour Author Type of Study N Primary Endpoint Platinum Benefit Target Sub-Population
Breast Cancer
Localized Tung 2020 [45] Randomized Phase II 118 pCR Cisplatin Platinum vs. Control: 18% vs. 26%. Risk ratio 0.70 (90% CI, 0.39–1.2). HER2-
I-III		 69% gBRCA1
30% gBRCA2
2% Both
Hahnen
2017 [47]		 Randomized Phase II 50 pCR Carboplatin Platinum vs. Control: 65.4% vs. 66.7%. Odds ratio 0.94 (0.29–3.095), (p = 0.92). TNBC
II-III		 17% gBRCA1/2
Advanced Isakoff 2015 [65] Phase II 86 ORR Cisplatin
Carboplatin		 BRCA1/2 mut vs. wild type: 54.5% vs. 19.7%, (p = 0.022). TNBC metastatic or locally recurrent unresectable 13% gBRCA1/2
77% wild type
10% not known
Pancreatic Cancer
Localized Golan 2020 [48] Retrospective analysis 61 pCR Oxaliplatin Mutated vs. non-mutated: 44.4% vs. 10%, (p = 0.009). Borderline resectable 23% gBRCA2
77% gBRCA wild type
Metastatic Okano 2020 [49] Phase II 43 OS Oxaliplatin 1-year survival 27.9% (90% CI 17–41.3).
Primary endpoint not met (30%).		 Metastatic PDAC Family history (ovarian, prostate, pancreatic, breast)
  • -

    BRCA not known
Wattenberg 2020 [50] Retrospective analysis 26 PFS Oxaliplatin
Cisplatin		 Mutated vs. non-mutated: 10.1 vs. 6.9 months, (p = 0.0068) Locally advanced or metastatic 33% Mutated:
  • -

    19.2% gBRCA1

  • -

    65.4% gBRCA2

  • -

    15.4% gPALB2

  • -

    67% Non-mutated
Prostate Cancer
Castration-resistant prostate cancer Schmid 2020 [51] Retrospective analysis 508 Platinum Antitumor activity (decrease PSA 50% and/or radiological response) Carboplatin
Cisplatin
Oxaliplatin		 Mutated (cohort 1) vs. non-mutated (cohort 2) decrease PSA: 47.1% vs. 36.1%, (p = 0.20). Advanced
  • -

    15.7% Mutated (cohort 1):

  • -

    55% BRCA2

  • -

    15% ATM

  • -

    3.8% BRCA1

  • -

    19.3% Non-mutated (cohort 2)

  • -

    65% Unknown (cohort 3)
Mota 2020 [52] Retrospective analysis 109 Platinum efficacy in DDR-mutant Carboplatin
Cisplatin		 67% BRCA2 achieved a PSA50 response (adjusted Odds Ratio 9.5; 95% CI 1.5–82.9) compared to DDRwt (13%), (p = 0.022). Metastatic
  • -

    PARPi naïve and prior taxane:

  • -

    9% BRCA2

  • -

    3% ATM

  • -

    6% CDK12

  • -

    6% FANCA

  • -

    1% PALB2

  • -

    75% DDRwt

pCR: Pathologic complete response; ORR: objective response rate; OS: overall survival; PFS: progression free survival; CI: confidence interval. g: germline mutation. PSA: prostate-specific antigen. DDR: DNA damage repair, including somatic and germline mutations in BRCA1/2, ATM, CDK12, FANCA and PALB2 genes. DDR wt: DDR wild type.